MarketBeat
08 Aug 2026, 06:04 UTC · 3h ago
Elanco Animal Health Q2 Earnings Call Highlights
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
08 Aug 2026, 06:04 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Elanco exceeded the high end of its prior guidance for revenue, adjusted EBITDA, and adjusted EPS for Q2 2026. — Beating the high end of guidance typically triggers an immediate positive re-rating of the stock due to improved earnings visibility.
+0.70The company raised its full-year organic constant-currency revenue growth outlook to 6%–7% and increased its innovation revenue target by $50 million to $1.25 billion. — Upward revisions to full-year guidance and innovation targets signal sustainable growth momentum beyond a single quarter.
+0.60Adjusted EPS rose 31% year-over-year to $0.34 and adjusted EBITDA increased 21% to $288 million. — Strong double-digit growth in profitability metrics indicates effective scaling and margin expansion.
+0.50Continue reading
6 related stories
Top 3 movers · tap to explore
Elanco reduced its year-end net leverage target to approximately 3 times, down from a prior 3-to-3.2-times range. — Lowering debt leverage improves the company's balance sheet health and reduces financial risk for investors.
+0.40The dermatology product Befrena is experiencing constrained supply, with unconstrained capacity not expected until early 2027. — Supply constraints limit the immediate revenue upside from a new product launch over the next two years.
-0.20Which stocks this story touches
The company exceeded guidance, raised its full-year outlook, showed strong organic revenue growth, and reported significant gains in market share for key pet-health products.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
MarketBeat
2h ago
